In pre-clinical models, prophylactic treatment with anti-PD-1 therapy expanded this CD8 + PD1 + population and led to an increase in HCC, while anti-PD-1 treatment in MeSH-HCC pre-clinical models also expanded this population in tumours but without tumour regression. Here, CD8A is linked to hepatocellular carcinoma.